Emerging drugs for hepatitis B

Bibliography

• LEE WM: Hepatitis B virus infection. N. Engl. J. Med. (1997) 337:1733-1745.
   PubMed Web of Science ®Google Scholar
• PERZ JF, ARMSTRONG GL, FARRINGTON LA, HUTIN YJ, BELL BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. (2006) 45:529-538.
   PubMed Web of Science ®Google Scholar
• ILOEJE UH, YANG HI, SU J, JEN CL, YOU SL, CHEN CJ: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 130:678-686.
   PubMed Web of Science ®Google Scholar
• CHEN CJ, YANG HI, SU J et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama (2006) 295:65-73.
   PubMed Web of Science ®Google Scholar
• STROFFOLINI T, MELE A, TOSTI ME et al.: The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J. Hepatol. (2000) 33:980-985.
   PubMed Web of Science ®Google Scholar
• LAVANCHY D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. (2004) 11:97-107.
   PubMed Web of Science ®Google Scholar
• CHANG M-H, CHEN C-J, LAI M-S et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. (1997) 336:1855-1859.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, LAU GK, BONINO F et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2004) 351:1206-1217.
   PubMed Web of Science ®Google Scholar
• LAU GK, PIRATVISUTH T, LUO KX et al.: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2005) 352:2682-2695.
   PubMed Web of Science ®Google Scholar
• ZOULIM F: Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res. (2004) 64:1-15.
   PubMed Web of Science ®Google Scholar
• LIAW YF, SUNG JJ, CHOW WC et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. (2004) 351:1521-1531.
   PubMed Web of Science ®Google Scholar
• COLONNO RJ, GENOVESI EV, MEDINA I et al.: Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. (2001) 184:1236-1245.
   PubMed Web of Science ®Google Scholar
• PURO V, DE CARLI G, CICALINI S et al.: European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro. Surveill. (2005) 10:260-264.
   PubMedGoogle Scholar
• VAN ZONNEVELD M, VAN NUNEN AB, NIESTERS HG, DE MAN RA, SCHALM SW, JANSSEN HL: Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J. Viral Hepat. (2003) 10:294-297.
   PubMed Web of Science ®Google Scholar
• LOK AS, MCMAHON BJ: Chronic hepatitis B. Hepatology (2007) 45:507-539.
   PubMed Web of Science ®Google Scholar
• LIAW YF, LEUNG N, GUAN R et al.: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. (2005) 25:472-489.
   PubMed Web of Science ®Google Scholar
• DE FRANCHIS R, HADENGUE A, LAU G et al.: EASL International Consensus Conference on Hepatitis B. 13 – 14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol. (2003) 39(Suppl. 1):S3-25.
   PubMed Web of Science ®Google Scholar
• YANG HI, LU SN, LIAW YF et al.: Hepatitis Be antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. (2002) 347:168-174.
   PubMed Web of Science ®Google Scholar
• REALDI G, FATTOVICH G, HADZYIANNIS S et al.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J. Hepatol. (1994) 21:656-666.
   PubMed Web of Science ®Google Scholar
• LOK AS, MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34:1225-1241.
   PubMed Web of Science ®Google Scholar
• JANSSEN HL, VAN ZONNEVELD M, SENTURK H et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 365:123-129.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, SCHIFF ER, WRIGHT TL et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. (1999) 341:1256-1263.
   PubMed Web of Science ®Google Scholar
• LAI CL, CHINE RW, LEUNG NWY et al.: A one year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. (1998) 339:61-68.
   PubMed Web of Science ®Google Scholar
• ZOULIM F: A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection. Drug Saf. (2002) 25:497-510.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 124:105-117.
   PubMed Web of Science ®Google Scholar
• LEUNG NW, LAI CL, CHANG TT et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 33:1527-1532.
   PubMed Web of Science ®Google Scholar
• ZOULIM F, POYNARD T, DEGOS F et al.: A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J. Viral Hepat.(2006) (In Press).
   Google Scholar
• LAI CL, DIENSTAG J, SCHIFF E et al.: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. (2003) 36:687-696.
   PubMed Web of Science ®Google Scholar
• LOK AS, LAI CL, LEUNG N et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 125:1714-1722.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPAIOANNOU C: Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2000) 32:847-851.
   PubMed Web of Science ®Google Scholar
• NAFA S, AHMED S, TAVAN D et al.: Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology (2000) 32:1078-1088.
   PubMed Web of Science ®Google Scholar
• LAMPERTICO P, VIGANO M, MANENTI E, IAVARONE M, LUNGHI G, COLOMBO M: Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 42:1414-1419.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, CHANG TT, Lim SG et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. (2003) 348:808-816.
   PubMed Web of Science ®Google Scholar
• LAI CL, ROSMAWATI M, LAO J et al.: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 123:1831-1838.
   PubMed Web of Science ®Google Scholar
• WOLTERS LM, HANSEN BE, NIESTERS HG, DEHERTOGH D, DE MAN RA: Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J. Hepatol. (2002) 37:137-144.
   PubMed Web of Science ®Google Scholar
• LAI CL, SHOUVAL D, LOK AS et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2006) 354:1011-1020.
   PubMed Web of Science ®Google Scholar
• CHANG TT, GISH RG, DE MAN R et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2006) 354:1001-1010.
   PubMed Web of Science ®Google Scholar
• ZOULIM F: Entecavir: a new treatment option for chronic hepatitis B. J. Clin. Virol. (2006) 36(1)8-12.
   PubMed Web of Science ®Google Scholar
• GISH R, CHANG TT, DE MAN RA et al.: Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients. Hepatology (2005) 42(Suppl. 1):A181, p267A.
   Google Scholar
• TENNEY DJ, LEVINE SM, ROSE RE et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. (2004) 48:3498-3507.
   PubMed Web of Science ®Google Scholar
• COLONNO RJ, ROSE R, LEVINE S et al.: Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology (2005) 42(Suppl. 1):A962, p573A.
   PubMed Web of Science ®Google Scholar
• ZOULIM F: Hepatitis B virus resistance to entecavir in nucleoside naive patients: does it exist? Hepatology (2006) 44:1404-1407.
   PubMed Web of Science ®Google Scholar
• TENNEY DJ, ROSE RE, BALDICK CJ et al.: Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. (2007) 51:902-911.
   PubMed Web of Science ®Google Scholar
• COLONNO RJ, ROSE R, BALDICK CJ et al.: Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology (2006) 44:1656-1665.
   PubMed Web of Science ®Google Scholar
• LAI CL, LIM SG, BROWN NA et al.: A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology (2004) 40:719-726.
   PubMed Web of Science ®Google Scholar
• LAI C, GANE E, LIAW Y-F et al.: Telbivudine versus lamivudine for chronic hepatitis B: first year results from the interantional phase III globe trial. Hepatology (2005) 42(Suppl. 1):LB01, p784A.
   Google Scholar
• LAI CL, LEUNG N, TEO EK et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 129:528-536.
   PubMed Web of Science ®Google Scholar
• BANI-SADR F, PALMER P, SCIEUX C, MOLINA JM: Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin. Infect Dis. (2004) 39:1062-1064.
   PubMed Web of Science ®Google Scholar
• BENHAMOU Y, TUBIANA R, THIBAULT V: Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N. Engl. J. Med. (2003) 348:177-178.
   PubMed Web of Science ®Google Scholar
• LACOMBE K, GOZLAN J, BOELLE PY et al.: Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. Aids (2005) 19:907-915.
   PubMed Web of Science ®Google Scholar
• DORE GJ, COOPER DA, POZNIAK AL et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. (2004) 189:1185-1192.
   PubMed Web of Science ®Google Scholar
• VAN BOMMEL F, WUNSCHE T, MAUSS S et al.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 40:1421-1425.
   PubMed Web of Science ®Google Scholar
• PETERS MG, ANDERSEN J, LYNCH P et al.: Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 44:1110-1116.
   PubMed Web of Science ®Google Scholar
• GISH RG, TRINH H, LEUNG N et al.: Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J. Hepatol. (2005) 43:60-66.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, MOMMEJA-MARIN H, SACKS SL et al.: A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology (2004) 40:140-148.
   PubMed Web of Science ®Google Scholar
• PEEK SF, COTE PJ, JACOB JR et al.: Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, l-arabinofura-nosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology (2001) 33:254-266.
   PubMed Web of Science ®Google Scholar
• JACQUARD AC, NASSAL M, PICHOUD C et al.: Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. (2004) 48:2683-2692.
   PubMed Web of Science ®Google Scholar
• LIN CC, XU C, TENG A, YEH LT, PETERSON J: Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. J. Clin. Pharmacol. (2005) 45:1250-1258.
   PubMed Web of Science ®Google Scholar
• KEEFFE EB, MARCELLIN P: New and emerging treatment of chronic hepatitis B. Clin. Gastroenterol. Hepatol. (2007) 5(3):285-294.
   PubMed Web of Science ®Google Scholar
• GISH RG: Clinical trial results of new therapies for HBV: implications for treatment guidelines. Semin. Liver Dis. (2005) 25(Suppl. 1):29-39.
   PubMedGoogle Scholar
• TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/Hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B [In Process Citation]. Hepatology (1999) 29:889-896.
   PubMed Web of Science ®Google Scholar
• RIZZETTO M, TASSOPOULOS NC, GOLDIN RD et al.: Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J. Hepatol. (2005) 42:173-179.
   PubMedGoogle Scholar
• DI MARCO V, MARZANO A, LAMPERTICO P et al.: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology (2004) 40:883-891.
   PubMed Web of Science ®Google Scholar
• RIZZETTO M: Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J. Med. Virol. (2002) 66:435-451.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPADIMITROPOULOS V, HADZIYANNIS SJ: Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology (2002) 36:219-226.
   PubMed Web of Science ®Google Scholar
• BUTI M, COTRINA M, JARDI R et al.: Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J. Viral Hepat. (2001) 8:270-275.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. (2003) 348:800-807.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2005) 352:2673-2681.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 13(16):1743-1751.
   Google Scholar
• YAO FY, TERRAULT NA, FREISE C, MASLOW L, BASS NM: Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology (2001) 34:411-416.
   PubMed Web of Science ®Google Scholar
• VILLENEUVE JP, CONDREAY LD, WILLEMS B et al.: Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 31:207-210.
   PubMed Web of Science ®Google Scholar
• SCHIFF ER, LAI CL, HADZIYANNIS S et al.: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 38:1419-1427.
   PubMed Web of Science ®Google Scholar
• VIERLING JM: Management of HBV infection in liver transplantation patients. Int. J. Med. Sci. (2005) 2:41-49.
   PubMedGoogle Scholar
• DORE GJ, GUAN R, WASIM JAFRI SM, SARIN SV, KEEFFE EB: Management of chronic hepatitis B in challenging patient populations. Liver Int. (2006) 26(Suppl. 2):38-46.
   Google Scholar
• ZOULIM F: Antiviral therapy of chronic hepatitis B. Antiviral Res. (2006) 71:206-215.
   PubMed Web of Science ®Google Scholar
• ZOULIM F: Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir. Chem. Chemother. (2004) 15:299-305.
   PubMedGoogle Scholar
• PERRILLO R, HANN HW, MUTIMER D et al.: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 126:81-90.
   PubMed Web of Science ®Google Scholar
• PETERS MG, HANN HW H, MARTIN P et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 126:91-101.
   PubMed Web of Science ®Google Scholar
• LAMPERTICO P, VIGANO M, MANENTI E, IAVARONE M, LUNGHI G, COLOMBO M: Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 42:1414-1419.
   PubMed Web of Science ®Google Scholar
• LAMPERTICO P, MARZANO A, LEVRERO M et al.: Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology (2006) 44:Abstract LB5, p693A.
   Google Scholar
• CHANG TT, GISH RG, HADZIYANNIS SJ et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 129:1198-1209.
   PubMed Web of Science ®Google Scholar
• VILLET S, OLLIVET A, PICHOUD C et al.: Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. (2007) (In Press).
   PubMedGoogle Scholar
• ANGUS P, VAUGHAN R, XIONG S et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125:292-297.
   PubMed Web of Science ®Google Scholar
• BRUNELLE MN, JACQUARD AC, PICHOUD C et al.: Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology (2005) 41:1391-1398.
   PubMed Web of Science ®Google Scholar
• VILLENEUVE JP, DURANTEL D, DURANTEL S et al.: Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. (2003) 39:1085-1089.
   PubMed Web of Science ®Google Scholar
• FUNG SK, ANDREONE P, HAN SH et al.: Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. (2005) 43:937-943.
   PubMed Web of Science ®Google Scholar
• VILLET S, PICHOUD C, VILLENEUVE JP, TREPO C, ZOULIM F: Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology (2006) 131:1253-1261.
   PubMed Web of Science ®Google Scholar
• BRUNELLE MN, JACQUARD AC, PICHOUD C et al.: Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology (2005) 41:1391-1398.
   PubMed Web of Science ®Google Scholar
• DURANTEL D, CARROUEE-DURANTEL S, WERLE-LAPOSTOLLE B et al.: A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology (2004) 40:855-864.
   PubMed Web of Science ®Google Scholar
• LAI CL, CHIEN RN, LEUNG NW et al.: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. (1998) 339:61-68.
   PubMed Web of Science ®Google Scholar
• MOMMEJA-MARIN H, MONDOU E, BLUM MR, ROUSSEAU F: Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology (2003) 37:1309-1319.
   PubMed Web of Science ®Google Scholar
• DI BISCEGLIE AM, LAI CL, GANE E et al.: Telbivudine globe trial: maximal early HBV suppression id predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology (2006) 44:Abstract 112, p230A.
   Google Scholar
• POYNARD T, ZOULIM F, RATZIU V et al.: Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am. J. Gastroenterol. (2005) 100:1970-1980.
   PubMed Web of Science ®Google Scholar
• SEEGER C, MASON WS: Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. (2000) 64:51-68.
   PubMed Web of Science ®Google Scholar
• GANEM D, PRINCE AM: Hepatitis B virus infection–natural history and clinical consequences. N. Engl. J. Med. (2004) 350:1118-1129.
   PubMed Web of Science ®Google Scholar
• SEIGNERES B, PICHOUD C, MARTIN P, FURMAN P, TREPO C, ZOULIM F: Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology (2002) 36:710-722.
   PubMed Web of Science ®Google Scholar
• MORALEDA G, SAPUTELLI J, ALDRICH CE, AVERETT D, CONDREAY L, MASON WS: Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. (1997) 71:9392-9399.
   PubMed Web of Science ®Google Scholar
• MASON WS, CULLEN J, MORALEDA G et al.: Lamivudine therapy of WHV-infected woodchucks. Virology (1998) 245:18-32.
   PubMed Web of Science ®Google Scholar
• JACQUARD AC, BRUNELLE MN, PICHOUD C et al.: In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′, 3′-dideoxy-3′-fluoroguanosine. Antimicrob. Agents Chemother. (2006) 50:955-961.
   PubMed Web of Science ®Google Scholar
• URBAN S, GRIPON P: Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein. J. Virol. (2002) 76:1986-1990.
   PubMed Web of Science ®Google Scholar
• DELANEY WET, EDWARDS R, COLLEDGE D et al.: Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob. Agents Chemother. (2002) 46:3057-3060.
   PubMed Web of Science ®Google Scholar
• DERES K, SCHRODER CH, PAESSENS A et al.: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science (2003) 299:893-896.
   PubMed Web of Science ®Google Scholar
• BLOCK TM, LU X, MEHTA AS et al.: Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med. (1998) 4:610-614.
   PubMed Web of Science ®Google Scholar
• ZOULIM F: New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J. Hepatol. (2005) 42:302-308.
   PubMed Web of Science ®Google Scholar
• TUTTLEMAN JS, POURCEL C, SUMMERS J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell (1986) 47:451-460.
   PubMed Web of Science ®Google Scholar
• WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S et al.: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 126:1750-1758.
   PubMed Web of Science ®Google Scholar
• POLLICINO T, BELLONI L, RAFFA G et al.: Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 130:823-837.
   PubMed Web of Science ®Google Scholar
• BERTOLETTI A, NAOUMOV NV: Translation of immunological knowledge into better treatments of chronic hepatitis B. J. Hepatol. (2003) 39:115-124.
   PubMed Web of Science ®Google Scholar
• WEBSTER GJ, REIGNAT S, BROWN D et al.: Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. (2004) 78:5707-5719.
   PubMed Web of Science ®Google Scholar
• PENNA A, ARTINI M, CAVALLI A et al.: Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest. (1996) 98:1185-1194.
   PubMed Web of Science ®Google Scholar
• GEHRING AJ, SUN D, KENNEDY PT et al.: The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J. Virol. (2007) 81:2940-2949.
   PubMed Web of Science ®Google Scholar
• GUIDOTTI LG, ROCHFORD R, CHUNG J, SHAPIRO M, PURCELL R, CHISARI FV: Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 284:825-829.
   PubMed Web of Science ®Google Scholar
• CAVANAUGH VJ, GUIDOTTI L, CHISARI FV: Interleukine-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. (1997) 71:3236-3243.
   PubMed Web of Science ®Google Scholar
• WIELAND SF, SPANGENBERG HC, THIMME R, PURCELL RH, CHISARI FV: Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc. Natl. Acad. Sci. USA (2004) 101:2129-2134.
   PubMed Web of Science ®Google Scholar
• FOUREL I, CULLEN JM, SAPUTELLI J et al.: Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. (1994) 68:8321-8330.
   PubMed Web of Science ®Google Scholar
• GUO JT, ZHOU H, LIU C et al.: Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections [In Process Citation]. J. Virol. (2000) 74:1495-1505.
   PubMed Web of Science ®Google Scholar
• SUMMERS J, JILBERT AR, YANG W et al.: Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc. Natl. Acad. Sci. USA (2003) 100:11652-11659.
   PubMed Web of Science ®Google Scholar
• SUMMERS J, MASON WS: Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc. Natl. Acad. Sci. USA (2004) 101:638-640.
   PubMed Web of Science ®Google Scholar
• MAYNARD M, PARVAZ P, DURANTEL S et al.: Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J. Hepatol. (2005) 42:279-281.
   PubMed Web of Science ®Google Scholar
• REHERMANN B, FERRARI C, PASQUINELLI C, CHISARI F: The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. (1996) 21:104-1108.
   Web of Science ®Google Scholar
• MENNE S, RONEKER CA, KORBA BE, GERIN JL, TENNANT BC, COTE PJ: Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-l-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol. (2002) 76:5305-5314.
   PubMed Web of Science ®Google Scholar
• ROLLIER C, SUNYACH C, BARRAUD L et al.: Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology (1999) 116:658-665.
   PubMed Web of Science ®Google Scholar
• LE GUERHIER F, THERMET A, GUERRET S et al.: Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J. Hepatol. (2003) 38:328-334.
   PubMed Web of Science ®Google Scholar
• MANCINI M, HADCHOUEL M, TIOLLAIS P, MICHEL ML: Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. J. Immunol. (1998) 161:5564-5570.
   PubMed Web of Science ®Google Scholar
• LU M, LOHRENGEL B, HILKEN G, KEMPER T, ROGGENDORF M: Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes. J. Virol. (2002) 76:58-67.
   PubMed Web of Science ®Google Scholar
• WANG J, GUJAR SA, COVA L, MICHALAK TI: Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J. Virol. (2007) 81:903-916.
   PubMed Web of Science ®Google Scholar
• SIEGEL F, LU M, ROGGENDORF M: Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection. J. Virol. (2001) 75:5036-5042.
   PubMed Web of Science ®Google Scholar
• MCKENZIE R, FRIED M, SALLIE R et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. (1995) 333:1099-1105.
   PubMed Web of Science ®Google Scholar
• LEWIS W, LEVINE E, GRINIUVENE B et al.: Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc. Natl. Acad. Sci. USA (1996) 93:3592-3597.
   PubMed Web of Science ®Google Scholar
• ZOULIM F: In vitro models for studying hepatitis B virus drug resistance. Semin. Liver Dis. (2006) 26:171-180.
   PubMed Web of Science ®Google Scholar
• YANG H, WESTLAND C, XIONG S, DELANEY WE: In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res. (2004) 61:27-36.
   PubMed Web of Science ®Google Scholar
• YANG H, QI X, SABOGAL A, MILLER M, XIONG S, DELANEY WET: Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir. Ther. (2005) 10:625-633.
   PubMed Web of Science ®Google Scholar
• DELANEY WET, RAY AS, YANG H et al.: Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. (2006) 50:2471-2477.
   PubMed Web of Science ®Google Scholar
• COLONNO RJ, ROSE R, LEVINE S et al.: Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology (2005) 42: 573A.
   Web of Science ®Google Scholar